XERS Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -29% compared to Xeris Biopharma Holdings's net margin of -49.65%. Xeris Biopharma Holdings's return on equity of -1019.2% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Xeris Biopharma Holdings has a consensus price target of --, signalling upside risk potential of 36.58%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that NovaBay Pharmaceuticals has higher upside potential than Xeris Biopharma Holdings, analysts believe NovaBay Pharmaceuticals is more attractive than Xeris Biopharma Holdings.

Xeris Biopharma Holdings has a beta of 1.812, which suggesting that the stock is 81.233% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Xeris Biopharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Xeris Biopharma Holdings quarterly revenues are $54.3M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Xeris Biopharma Holdings's net income of -$15.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Xeris Biopharma Holdings's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings is 2.68x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -29% compared to Xeris Biopharma Holdings's net margin of -2357.27%. Xeris Biopharma Holdings's return on equity of -1019.2% beat Palatin Technologies's return on equity of --.

Xeris Biopharma Holdings has a consensus price target of --, signalling upside risk potential of 36.58%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Palatin Technologies has higher upside potential than Xeris Biopharma Holdings, analysts believe Palatin Technologies is more attractive than Xeris Biopharma Holdings.

Xeris Biopharma Holdings has a beta of 1.812, which suggesting that the stock is 81.233% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Xeris Biopharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Xeris Biopharma Holdings quarterly revenues are $54.3M, which are larger than Palatin Technologies quarterly revenues of $350K. Xeris Biopharma Holdings's net income of -$15.7M is lower than Palatin Technologies's net income of -$7.8M. Notably, Xeris Biopharma Holdings's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings is 2.68x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -29% compared to Xeris Biopharma Holdings's net margin of --. Xeris Biopharma Holdings's return on equity of -1019.2% beat Theriva Biologics's return on equity of --.

Xeris Biopharma Holdings has a consensus price target of --, signalling upside risk potential of 36.58%. On the other hand Theriva Biologics has an analysts' consensus of $100.00 which suggests that it could grow by 7838.6%. Given that Theriva Biologics has higher upside potential than Xeris Biopharma Holdings, analysts believe Theriva Biologics is more attractive than Xeris Biopharma Holdings.

Xeris Biopharma Holdings has a beta of 1.812, which suggesting that the stock is 81.233% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.329, suggesting its more volatile than the S&P 500 by 32.874%.

Xeris Biopharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Xeris Biopharma Holdings quarterly revenues are $54.3M, which are larger than Theriva Biologics quarterly revenues of --. Xeris Biopharma Holdings's net income of -$15.7M is lower than Theriva Biologics's net income of -$7.7M. Notably, Xeris Biopharma Holdings's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings is 2.68x versus 0.90x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

Zevra Therapeutics has a net margin of -29% compared to Xeris Biopharma Holdings's net margin of -899.19%. Xeris Biopharma Holdings's return on equity of -1019.2% beat Zevra Therapeutics's return on equity of -159.89%.

Xeris Biopharma Holdings has a consensus price target of --, signalling upside risk potential of 36.58%. On the other hand Zevra Therapeutics has an analysts' consensus of -- which suggests that it could grow by 135.57%. Given that Zevra Therapeutics has higher upside potential than Xeris Biopharma Holdings, analysts believe Zevra Therapeutics is more attractive than Xeris Biopharma Holdings.

Xeris Biopharma Holdings has a beta of 1.812, which suggesting that the stock is 81.233% more volatile than S&P 500. In comparison Zevra Therapeutics has a beta of 1.972, suggesting its more volatile than the S&P 500 by 97.163%.

Xeris Biopharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zevra Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings pays -- of its earnings as a dividend. Zevra Therapeutics pays out -- of its earnings as a dividend.

Xeris Biopharma Holdings quarterly revenues are $54.3M, which are larger than Zevra Therapeutics quarterly revenues of $3.7M. Xeris Biopharma Holdings's net income of -$15.7M is higher than Zevra Therapeutics's net income of -$33.2M. Notably, Xeris Biopharma Holdings's price-to-earnings ratio is -- while Zevra Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings is 2.68x versus 14.75x for Zevra Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.